Recorded Chinese product: 尼莫地平片尼莫地平片

This is a medicine registration record from NMPA data.本页为国家药监局药品注册记录。

Labeled sections from the recorded Chinese source are included below. English wording is a reference translation when one is on file, not an official English label.本记录未接入产品级适应症/安全性标注字段。

生产企业Manufacturer

主要成分Active Ingredients

药物知识说明

尼莫地平是一种在国家药监局注册认定的药品。该药品含有尼莫地平-43853285等成分。

该药品关联的活性成分包括:尼莫地平Nimo Diping。这些成分信息来自国家药监局数据库。

该药品标注的生产企业为:湖南百草制药有限公司Chinese legal name: 湖南百草制药有限公司。

您可以探索含有相同成分的其他药品:尼莫地平-43853285成分药品。

本页面内容来自国家药监局数据库,MedicineGraph在此基础上提供关系图谱和知识导航。

Medicine Knowledge

This medicine (original name: 尼莫地平片) is a medicine registered with the national drug regulatory authority. It contains recorded ingredients as active ingredient(s).

Active ingredients associated with this product: 尼莫地平Nimo Diping.

Manufacturers recorded for this product: 湖南百草制药有限公司Chinese legal name: 湖南百草制药有限公司.

Explore other medicines containing the same ingredient: 尼莫地平 productsProducts containing this recorded ingredient.

Source: MedicineGraph authoritative database. Relationships derived from registered product information.

这是什么What is this

  • 通用名/品名Recorded product name: 尼莫地平片Recorded Chinese product: 尼莫地平片
  • 剂型Dosage form: 片剂Tablets
  • 规格Specification: 20mg20 mg

本段仅展示注册/说明书已记录的身份属性,不含适应症或用法建议。Identity attributes from registration/leaflet records only; no indications or usage advice.

主要成分Ingredients

生产企业Manufacturer

  • 湖南百草制药有限公司Chinese legal name: 湖南百草制药有限公司

注册信息NMPA approval number

  • 批准文号NMPA approval number: 国药准字H43020644

信息来源Source and scope

国家药品监督管理局(中国)药品注册数据及已接入说明书字段。National Medical Products Administration (China) medicine-registration data and linked leaflet fields.

  • 品名来源Name source: 10多万条药品说明书数据库 (HIGH)Package-insert database (more than 100,000 records) (HIGH)
  • 生产企业来源Manufacturer source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
  • 剂型来源Dosage-form source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)

范围:当前 MedicineGraph 注册记录及已记录的精确关系;非完整目录,亦不构成疗效等同主张,也不支持换用判断。不含适应症/安全性推断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence. No inferred indications/safety.

本段为已核准说明书原文摘录(非改写、非AI摘要),非正式英文标签,亦不构成用药建议。 Not an official English label and not medical advice. English wording, when shown, is a reference translation of the Chinese source label.

English translation for reference. Translated from the Chinese source label. Not an official English label and not medical advice.

NMPA approval number

国药准字H43020644

Manufacturer

Chinese legal name: 湖南百草制药有限公司 (domestically manufactured)

Indications

English translation unavailable. The original Chinese source label remains available below.

Dosage and administration

English translation unavailable. The original Chinese source label remains available below.

Adverse reactions

English translation unavailable. The original Chinese source label remains available below.

Contraindications

English translation unavailable. The original Chinese source label remains available below.

Precautions

English translation unavailable. The original Chinese source label remains available below.

Storage

English translation unavailable. The original Chinese source label remains available below.

Specification

English translation unavailable. The original Chinese source label remains available below.

中文说明书原文Original Chinese source label

批准文号

国药准字H43020644

生产企业

湖南百草制药有限公司(国产)

适应症

本品钙拮抗剂,本品用于缺血性脑血管病、偏头痛、轻度蛛网膜下腔出血所致脑血管痉挛、突发性耳聋、轻、中度高血压。

用法用量

按下述方法服用,或遵医嘱。|1.缺血性脑血管病: 口服,每日80~120mg(4~6片),分3次服用,连服一个月。|2.偏头痛:口服,一次40mg(2片),一日3次,12周为一疗程,有效率达88%,约有一半病例可基本痊愈或显效,对血管性、紧张性和丛集性以及混合型头痛等均能减轻疼痛程度,减少发作频率和持续时间,并能防止先兆症状的出现。|3.蛛网膜下腔出血所引起的脑血管痉挛:口服,一次40~60mg(2~3片),一日3~4次,3~4周为一疗程,如需手术的患者,手术当天停药,以后可继续服用。|4.突发性耳聋:口服,一日40~60mg(2~3片),分三次服用,5天为一疗程,一般用药3~4疗程。|5.轻、中度高血压病:高血压病合并有上述脑血管病者,可优先选用。口服,开始一次40mg(2片),一日3次,一日最大剂量为240mg(12片)。

不良反应

大量临床实践证明,蛛网膜下隙出血者应用尼莫地平治疗时约有 11.2% 的病者出现不良反应。最常见的不良反应有:|1. 血压下降,血压下降的程度与药物剂量有关。|2. 肝炎。|3. 皮肤刺痛。|4. 胃肠道出血。|5. 血小板减少。|6. 偶见一过性头晕、头痛、面潮红、呕吐、胃肠不适等。此外,口服尼莫地平以后,个别病人可发生碱性磷酸酶 (ALP) ?乳酸脱氢酶 (LDH) ? AKP 的升高,血糖升高以及个别人的血小板数的升高。

禁忌

药物可由乳汁分泌,哺乳期妇女不宜应用。

注意事项

1. 脑水肿及颅内压增高患者须慎用。|2. 尼莫地平的代谢产物具有毒性反应,肝功能损害者应当慎用。|3. 本品可引起血压的降低。在高血压合并蛛网膜下隙出血或脑卒中患者中,应注意减少或暂时停用降血压药物,或减少本品的用药剂量。|4. 可产生假性肠梗阻,表现为腹胀、肠鸣音减弱。当出现上述症状时应当减少用药剂量和保持观察。|5. 避免与β-阻断剂或其他钙拮抗剂合用。

贮藏

密封、在干燥处保存。

规格

20mg

证据Evidence

  • 批准文号: 国药准字H43020644
  • rights: 本段为已核准说明书原文摘录(非改写、非AI摘要),非正式英文标签,亦不构成用药建议。

信息来源Source and scope

国家药品监督管理局(中国)药品注册数据。National Medical Products Administration (China) medicine-registration data.

范围:当前 MedicineGraph 注册记录及已记录的精确关系;非完整目录,亦不构成疗效等同主张,也不支持换用判断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence.